miR-146a acted as a regulatory in CAD patients by affecting the expression of interleukin-1 receptor-associated kinase 1 (IRAK1) and tumor necrosis factor receptor associated factor 6 (TRAF6), which were involved in the TLR and IL-1 receptor (IL-1R) signaling pathway, and CAD patients exhibited an increased expression level of miR-146a [17], indicating its effect on CAD. The gene discussed is IRAK1; the disease is coronary artery disorder.